晚期非小细胞肺癌3种化疗方案的药物经济学评价  

Pharmacoeconomic Evaluation of Three Chemotherapy Regimens for Advanced Non-small Cell Lung Cancer

作　　者：王冬梅[1] 莫遗盛[1] 湛永滋[1] 王湘萍[1] 

机构地区：[1]广西医科大学第三附属医院,南宁530031

出　　处：《中国医院用药评价与分析》2012年第5期388-390,共3页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：广西卫生厅项目(编号:Z2007330)

摘　　要：目的:探讨治疗晚期非小细胞肺癌3种化疗方案的经济学效果。方法:运用药物经济学原理对多西他赛+卡铂(A组)、吉西他滨+卡铂(B组)、多西他赛+吉西他滨(C组)3种化疗方案的成本-效果进行分析。结果:3组成本分别为12 700、14 160、17 280元;有效率分别为48.0%、46.9%、47.1%;成本-效果比分别为264.6、301.9、366.9;B、C组相对于A组的增量成本-效果比分别为-1 327.3、-5 088.9。结论:A组治疗晚期非小细胞肺癌最佳。OBJECTIVE： To evaluate the economic effectiveness of 3 chemotherapeutic regimens in the treatment of advanced non-small cell lung cancer（NSCLC）.METHODS： The principle of pharmacoeconomics was adopted in the cost-effectiveness analysis of 3 chemotherapeutic regimens in the treatment of advanced NSCLC including docetaxel plus carboplatin（group A）,gemcitabine plus carboplatin（group B） and docetaxel plus gemcitabine（group C）.RESULTS： The costs in 3 groups were 12 700 yuan,14 160 yuan and 17 280 yuan respectively.The effective rates were 48.0%,46.9% and 47.1%,respectively.The cost-effectiveness ratios were 264.6,301.9 and 366.9,respectively.Compared with group A,the incremental cost-effectiveness ratios of group B and group C were-1 327.3 and-5 088.9,respectively.CONCLUSION： Docetaxe plus carboplatin（group A） was proved to be the preferred regimen for advanced NSCLC pharmacoeconomically.

关 键 词：晚期非小细胞肺癌 药物经济学 成本-效果分析 

分 类 号：R979.1[医药卫生—药品]